Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2014-08-29 05:49:15 UTC |
---|
Update Date | 2014-12-24 20:26:41 UTC |
---|
Accession Number | T3D4172 |
---|
Identification |
---|
Common Name | Guanidine |
---|
Class | Small Molecule |
---|
Description | Guaniidine is a uremic toxin. Uremic toxins can be subdivided into three major groups based upon their chemical and physical characteristics: 1) small, water-soluble, non-protein-bound compounds, such as urea; 2) small, lipid-soluble and/or protein-bound compounds, such as the phenols and 3) larger so-called middle-molecules, such as beta2-microglobulin. Chronic exposure of uremic toxins can lead to a number of conditions including renal damage, chronic kidney disease and cardiovascular disease.
Guanidine is a polyamine that can function as a strong organic base existing primarily as guanidium ions at physiological pH. With a pKa of 12.5, guanidine is protonated, with a charge of +1 in physiological conditions. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed). Guanidine is a crystalline compound of strong alkalinity formed by the oxidation of guanine. It is used in the manufacture of plastics and explosives. |
---|
Compound Type | - Amide
- Amine
- Drug
- Food Toxin
- Metabolite
- Natural Compound
- Organic Compound
- Uremic Toxin
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | (4-Aminobutyl) guanidine | Aminoformamidine | Aminomethanamidine | Carbamamidine | Carbamidine | Gu | Guanidin | GUANIDINE | H2N-C(=NH)-NH2 | Imidourea | Iminourea |
|
---|
Chemical Formula | CH5N3 |
---|
Average Molecular Mass | 59.071 g/mol |
---|
Monoisotopic Mass | 59.048 g/mol |
---|
CAS Registry Number | 113-00-8 |
---|
IUPAC Name | guanidine |
---|
Traditional Name | guanidine |
---|
SMILES | NC(N)=N |
---|
InChI Identifier | InChI=1S/CH5N3/c2-1(3)4/h(H5,2,3,4) |
---|
InChI Key | InChIKey=ZRALSGWEFCBTJO-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as guanidines. Guanidines are compounds containing a guanidine moiety, with the general structure (R1R2N)(R3R4N)C=N-R5. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic nitrogen compounds |
---|
Class | Organonitrogen compounds |
---|
Sub Class | Guanidines |
---|
Direct Parent | Guanidines |
---|
Alternative Parents | |
---|
Substituents | - Guanidine
- Carboximidamide
- Organopnictogen compound
- Hydrocarbon derivative
- Imine
- Aliphatic acyclic compound
|
---|
Molecular Framework | Aliphatic acyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Endogenous |
---|
Cellular Locations | |
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | - Adrenal Cortex
- Adrenal Gland
- Adrenal Medulla
- Brain
- Cartilage
- Fibroblasts
- Intestine
- Kidney
- Liver
- Muscle
- Nerve Cells
- Pancreas
- Placenta
- Platelet
- Spleen
- Testes
|
---|
Pathways | Not Available |
---|
Applications | Not Available |
---|
Biological Roles | Not Available |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Appearance | White powder. |
---|
Experimental Properties | Property | Value |
---|
Melting Point | 50°C | Boiling Point | Not Available | Solubility | 1840 mg/L (at 20°C) | LogP | -0.6 |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
GC-MS | GC-MS Spectrum - GC-MS (3 TMS) | splash10-00dj-0920000000-b2c19a9125b059b573fd | 2014-06-16 | View Spectrum | GC-MS | GC-MS Spectrum - GC-MS (Non-derivatized) | splash10-00dj-0920000000-b2c19a9125b059b573fd | 2017-09-12 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4i-9000000000-6e00e9be1957670e422b | 2017-09-01 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated) | splash10-03di-9000000000-4df2949d18a754b6aa19 | 2012-07-24 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated) | splash10-0006-9000000000-18b92fabd8878a75412f | 2012-07-24 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated) | splash10-0006-9000000000-6675e99565dbe0735311 | 2012-07-24 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-03di-9000000000-0bf566c21de369198214 | 2015-04-24 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-03di-9000000000-b4670d41c5cfae856086 | 2015-04-24 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-03dl-9000000000-9431377731da436c5aa7 | 2015-04-24 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0a4i-9000000000-2280b2044ac4a1f8b7fb | 2015-04-25 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0a4i-9000000000-8278836749ed05b02fb3 | 2015-04-25 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0006-9000000000-154d1302bda42480ad7b | 2015-04-25 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0006-9000000000-ab782a456c989f06bfc8 | 2021-09-22 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0006-9000000000-36e3aa30c6cc4afb2049 | 2021-09-22 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0006-9000000000-36e3aa30c6cc4afb2049 | 2021-09-22 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0006-9000000000-1c8520c5f7efb1187e43 | 2021-09-23 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0006-9000000000-1c8520c5f7efb1187e43 | 2021-09-23 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0006-9000000000-1c8520c5f7efb1187e43 | 2021-09-23 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Rapidly absorbed and distributed |
---|
Mechanism of Toxicity | Uremic toxins such as guaniidine are actively transported into the kidneys via organic ion transporters (especially OAT3). Increased levels of uremic toxins can stimulate the production of reactive oxygen species. This seems to be mediated by the direct binding or inhibition by uremic toxins of the enzyme NADPH oxidase (especially NOX4 which is abundant in the kidneys and heart) (2). Reactive oxygen species can induce several different DNA methyltransferases (DNMTs) which are involved in the silencing of a protein known as KLOTHO. KLOTHO has been identified as having important roles in anti-aging, mineral metabolism, and vitamin D metabolism. A number of studies have indicated that KLOTHO mRNA and protein levels are reduced during acute or chronic kidney diseases in response to high local levels of reactive oxygen species (3). |
---|
Metabolism | Not metabolized.
Half Life: 7-8 hours |
---|
Toxicity Values | LD50 = 475 mg/kg (oral, rat). |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
---|
Uses/Sources | For the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis. |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Chronic exposure to uremic toxins can lead to a number of conditions including renal damage, chronic kidney disease and cardiovascular disease. |
---|
Symptoms | As a uremic toxin, this compound can cause uremic syndrome. Uremic syndrome may affect any part of the body and can cause nausea, vomiting, loss of appetite, and weight loss. It can also cause changes in mental status, such as confusion, reduced awareness, agitation, psychosis, seizures, and coma. Abnormal bleeding, such as bleeding spontaneously or profusely from a very minor injury can also occur. Heart problems, such as an irregular heartbeat, inflammation in the sac that surrounds the heart (pericarditis), and increased pressure on the heart can be seen in patients with uremic syndrome. Shortness of breath from fluid buildup in the space between the lungs and the chest wall (pleural effusion) can also be present. |
---|
Treatment | Kidney dialysis is usually needed to relieve the symptoms of uremic syndrome until normal kidney function can be restored. |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB00536 |
---|
HMDB ID | HMDB01842 |
---|
PubChem Compound ID | 3520 |
---|
ChEMBL ID | CHEMBL821 |
---|
ChemSpider ID | 3400 |
---|
KEGG ID | C17349 |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 24435 |
---|
BioCyc ID | CPD-593 |
---|
CTD ID | Not Available |
---|
Stitch ID | Not Available |
---|
PDB ID | GAI |
---|
ACToR ID | Not Available |
---|
Wikipedia Link | Guanidine |
---|
References |
---|
Synthesis Reference | Helmut Hoffmann, Carlhans Suling, “Process for the production of guanidine salts of aliphatic mercaptosulphonic acids.” U.S. Patent US3956368, issued November, 1954. |
---|
MSDS | Link |
---|
General References | - Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012 Jul;23(7):1258-70. doi: 10.1681/ASN.2011121175. Epub 2012 May 24. [22626821 ]
- Schulz AM, Terne C, Jankowski V, Cohen G, Schaefer M, Boehringer F, Tepel M, Kunkel D, Zidek W, Jankowski J: Modulation of NADPH oxidase activity by known uraemic retention solutes. Eur J Clin Invest. 2014 Aug;44(8):802-11. doi: 10.1111/eci.12297. [25041433 ]
- Young GH, Wu VC: KLOTHO methylation is linked to uremic toxins and chronic kidney disease. Kidney Int. 2012 Apr;81(7):611-2. doi: 10.1038/ki.2011.461. [22419041 ]
- De Deyn PP, Marescau B, D'Hooge R, Possemiers I, Nagler J, Mahler C: Guanidino compound levels in brain regions of non-dialyzed uremic patients. Neurochem Int. 1995 Sep;27(3):227-37. [8520461 ]
- Bullough A, Karadia S, Watters M: Phaeochromocytoma: an unusual cause of hypertension in pregnancy. Anaesthesia. 2001 Jan;56(1):43-6. [11167434 ]
- Mannik M, Person RE: Deep penetration of antibodies into the articular cartilage of patients with rheumatoid arthritis. Rheumatol Int. 1994;14(3):95-102. [7839077 ]
- Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [10385678 ]
- Eropkin MIu, Smirnova TD, Eropkina EM, Mamaeva EG: [The study of the Ca2+ role in cytotoxic response of human cells in culture to the action of xenobiotics]. Tsitologiia. 2000;42(2):154-9. [10752119 ]
- Rufanova VA, Sorokin A: CrkII associates with BCAR3 in response to endothelin-1 in human glomerular mesangial cells. Exp Biol Med (Maywood). 2006 Jun;231(6):752-6. [16740993 ]
- Bjornsson S: Size-dependent separation of proteoglycans by electrophoresis in gels of pure agarose. Anal Biochem. 1993 May 1;210(2):292-8. [8512064 ]
- Sakamoto N, Toge T, Nishiyama M: Tumor-specific synergistic therapy of mitomycin C: modulation of bioreductive activation. Hiroshima J Med Sci. 1997 Jun;46(2):67-73. [9232934 ]
- Lorenzo P, Bayliss MT, Heinegard D: A novel cartilage protein (CILP) present in the mid-zone of human articular cartilage increases with age. J Biol Chem. 1998 Sep 4;273(36):23463-8. [9722583 ]
- Dabaghian RH, Barnard G, McConnell I, Clewley JP: An immunoassay for the pathological form of the prion protein based on denaturation and time resolved fluorometry. J Virol Methods. 2006 Mar;132(1-2):85-91. Epub 2005 Oct 10. [16219367 ]
- Gothert M, Bruss M, Bonisch H, Molderings GJ: Presynaptic imidazoline receptors. New developments in characterization and classification. Ann N Y Acad Sci. 1999 Jun 21;881:171-84. [10415912 ]
- Okumi M, Ueda T, Ichimaru N, Fujimoto N, Itoh K: [A case of composite pheochromocytoma-ganglioneuroblastoma in the adrenal gland with primary hyperparathyroidism]. Hinyokika Kiyo. 2003 May;49(5):269-72. [12822455 ]
- Leitersdorf E, Reshef A, Meiner V, Levitzki R, Schwartz SP, Dann EJ, Berkman N, Cali JJ, Klapholz L, Berginer VM: Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews or Moroccan origin. J Clin Invest. 1993 Jun;91(6):2488-96. [8514861 ]
- Atlas D: Molecular and physiological properties of clonidine-displacing substance. Ann N Y Acad Sci. 1995 Jul 12;763:314-24. [7677341 ]
- Mizutani N, Hayakawa C, Ohya Y, Watanabe K, Watanabe Y, Mori A: Guanidino compounds in hyperargininemia. Tohoku J Exp Med. 1987 Nov;153(3):197-205. [3433275 ]
- Rubello D, Bui C, Casara D, Gross MD, Fig LM, Shapiro B: Functional scintigraphy of the adrenal gland. Eur J Endocrinol. 2002 Jul;147(1):13-28. [12088915 ]
- Wang JG, Lemon SM: Hepatitis delta virus antigen forms dimers and multimeric complexes in vivo. J Virol. 1993 Jan;67(1):446-54. [7677957 ]
- Maruta K, Sonoda Y, Saigo R, Yoshioka T, Fukunaga H: [A patient with von Recklinghausen's disease associated with polymyositis, asymptomatic pheochromocytoma, and primary hepatic leiomyosarcoma]. Nihon Ronen Igakkai Zasshi. 2004 May;41(3):339-43. [15237755 ]
- Noyori K, Koshino T, Takagi T, Okamoto R, Jasin HE: Binding characteristics of antitype II collagen antibody to the surface of diseased human cartilage as a probe for tissue damage. J Rheumatol. 1994 Feb;21(2):293-6. [8182639 ]
- Tapiero H, Mathe G, Couvreur P, Tew KD: I. Arginine. Biomed Pharmacother. 2002 Nov;56(9):439-45. [12481980 ]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Not Available |
---|
Down-Regulated Genes | Not Available |
---|